Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Post by newdaydawningon Sep 23, 2019 8:56pm

364 Views

Post# 30157045

Applying the 80-20 rule to TLT

Everyone's heard of the 80/20 or 20/80 rule. Google it.

Here's my spin on what it could mean to TLT. Let's say after 20 patients, we post 80% 12-month CR.

Would that be enough to tip this trial into the fast lane? I welcome discussion.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal